Can-Fite's Namodenoson Clears the Safety Bar in Phase 2a Pancreatic Cancer Study

Can-Fite BioPharma stepped into the spotlight after reporting positive Phase 2a results for its cancer candidate namodenoson in one of oncology's toughest settings.

Can-Fite is a clinical-stage biotech developing orally administered small-molecule drugs for cancer and inflammatory disease, with namodenoson among its lead assets. The Phase 2a study tested the drug in advanced pancreatic ductal adenocarcinoma, a disease with few options once standard therapy fails.

The upside case is built on the trial's results. Can-Fite said the open-label study met its primary safety endpoint and that namodenoson was well tolerated across 20 heavily pretreated patients — 14 who received it as third-line therapy, five as second-line and one as fourth-line. The company highlighted durable survival despite advanced disease, noting that one second-line patient remained alive more than 18 months. Can-Fite plans a Phase 2b study combining namodenoson with gemcitabine, and the data were accepted for poster presentation at the ESMO Congress 2026.

However, a 20-patient, open-label Phase 2a without a control arm is far from proof of efficacy, and pancreatic cancer has defeated many drug candidates. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.